I-Stable Buyback evela kumakhasimende CAS 782487-28-9 Rosiptor Ikhwalithi Enhle Intengo Engcono Kakhulu Ukuthengisa Okushisayo Ukuphepha Kwesitoko Ukuthumela Ukuhlanzeka Okuphezulu 99% -ikhophi

Umkhiqizo wokuqala we-semaglutide wathuthukiswa nguNovo Nordisk futhi ukhonjiswa abantu abadala abanesifo sikashukela sohlobo 2. Igama lokuhweba lomkhiqizo womjovo i-Ozempic®, engasetshenziswa kanye ngesonto. Igunyazwe ukumakethwa yi-US Food and Drug Administration (FDA) ngomhla ka-5 Disemba 2017, kanye ne-European Medicines Agency (EMA) ngomhla ka-Febhruwari 8, 2018. Yagunyazelwa ukumakethwa yi-Japan Pharmaceuticals and Medical Devices Agency ( PMDA) ngoMashi 23, 2018. Isicelo sokumaketha sathunyelwa kwa-China Medical Products Administration (NMPA) ngo-April 4, 2020, futhi okwamanje siyabuyekezwa futhi sivunyelwe. Igama lomkhiqizo we-chemicalbook lomkhiqizo wethebhulethi yomlomo, i-Rybelsus®, lagunyazwa yi-FDA ngoSepthemba 20, 2019, i-European EMA ngoMashi 2020, kanye ne-PMDA yaseJapan ngoJuni 2020. Umuthi wokuqala ophathwayo emhlabeni we-GLP- 1. I-Semaglutide (i-0.5 mg noma i-1 mg injection) ingasetshenziswa ukwelapha uhlobo lwe-2 yesifo sikashukela kubantu abadala. Lo muthi uyi-glucagon-like peptide (GLP-1) receptor agonist, evuselela ukukhiqizwa kwe-insulin futhi yehlise ukukhiqizwa kweglucagon. Ingxenye yempilo yokubophezela ku-albumin yegazi yiviki elingu-1, ngakho-ke kufanele inikezwe kanye ngesonto ngepeni eligcwaliswe ngaphambili. Isiza ngokudla kanye nokuzivocavoca ukuthuthukisa ukulawula ushukela egazini kubantu abadala abanesifo sikashukela sohlobo 2.